Drug intelligence / Profile preview

3,4,5-trimethoxyamphetamine

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral
01

Overview

3,4,5-Trimethoxyamphetamine (TMA) is a synthetic psychedelic and hallucinogenic compound belonging to the amphetamine class. It acts primarily as a serotonergic psychedelic with modest agonist activity at serotonin receptors such as 5-HT2A and 5-HT2C. TMA produces hallucinogenic effects at doses of approximately 100–250 mg with a duration of action lasting about 6–8 hours. It is structurally related to mescaline but is more potent by weight and has a shorter duration of action. TMA has appeared on the illicit drug market and is classified as a Schedule I controlled substance in the United States[1][2][6][8]. There are no approved medical indications or pharmaceutical uses for this compound.

Other names
mescalamphetamine3,4,5-trimethoxy-α-methyl-benzeneethanamine
02

Targets

5-HT2C (5-hydroxytryptamine receptor 2C)

Beyond the preview

Go deeper on 3,4,5-trimethoxyamphetamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3,4,5-trimethoxyamphetamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call